Recovery & Repair
EPO-derived helix-B peptide
Vial Content
For laboratory & research use only — not for human or animal consumption. You must be 18+ to purchase.
Overview
ARA-290 (cibinetide) is an 11-residue peptide derived from the helix-B surface of erythropoietin. It was designed to engage the tissue-protective innate-repair receptor while leaving EPO's blood-cell-stimulating activity behind — which is exactly what makes it interesting: the repair signalling, isolated from the hematopoietic one.
ARA-290 lets protocols study EPO-pathway tissue protection without the confound of erythropoiesis, a separation the parent hormone cannot offer. It has a substantial research literature in neuropathy and tissue-protection models. REPRIME supplies a lyophilized 30 mg vial — generous capacity for extended protocols, with reconstitution under the researcher's control.
Engineered selectivity deserves verified identity. Every batch is independently HPLC-tested and released at ≥99% main-peak purity, with the batch COA published in the Certificates repository. The 30 mg lyophilized vial ships cold-chain in tamper-evident packaging with a unique REP-XXXX-XXXX-X code — one scan at first use confirms it is genuine. For laboratory and research use only; not for human consumption.
Store lyophilized at -20°C. After reconstitution, refrigerate at 2-8°C.
Ships within Egypt 1–3 business days via insulated courier.
Documents
Documents will appear here once the lab reports are uploaded.
FAQ
An 11-residue peptide derived from erythropoietin's helix-B surface, studied for tissue-protective signalling separated from EPO's blood-cell effects.
As a lyophilized 30 mg vial, HPLC-verified at ≥99% purity with a batch-specific COA and verification code.
Related
Copper-tripeptide complex
